Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables
about
Pediatric medulloblastoma - update on molecular classification driving targeted therapiesCombined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable diseaseMolecular subgroups of medulloblastoma: the current consensusItraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonistsAdvances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumorsCross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenanceVismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsiesIntracranial cystic lesions: a review.Differential expression of folate receptor 1 in medulloblastoma and the correlation with clinicopathological characters and target therapeutic potentialInhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors.Actionable molecular biomarkers in primary brain tumors.Analysis of different medulloblastoma histotypes by two-dimensional gel and MALDI-TOF.Reporting tumor molecular heterogeneity in histopathological diagnosis.Mutation and expression analysis in medulloblastoma yields prognostic variants and a putative mechanism of disease for i17q tumors.Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumorsNos2 inactivation promotes the development of medulloblastoma in Ptch1(+/-) mice by deregulation of Gap43-dependent granule cell precursor migration.Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.Declining childhood and adolescent cancer mortality: great progress but still much to be done.Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivorsMolecular subgroups of medulloblastoma.Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape.Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-propertiesThe molecular classification of medulloblastoma: driving the next generation clinical trials.Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi AnemiaOutcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study.Novel cell lines established from pediatric brain tumors.Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangementDisseminated carcinoma ex pleomorphic adenoma in an adolescent confirmed by application of PLAG1 immunohistochemistry and FISH for PLAG1 rearrangementFunctional genomics identifies drivers of medulloblastoma dissemination.Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy.Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variantsMolecular diagnostics in embryonal brain tumors.Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trialCTNNB1, AXIN1 and APC expression analysis of different medulloblastoma variants.MR Imaging Characteristics of Wingless-Type-Subgroup Pediatric Medulloblastoma.
P2860
Q21129295-D2F5754C-E381-456F-AE68-C2C8A8C537C3Q24310764-93E90B34-C57F-4A6B-8996-A071A69D0266Q24615271-A4E490CF-C2C8-4504-B2D0-16D5D1A25F87Q24632161-A2973437-F825-4516-8EC2-64D37CB865C2Q26866408-0D3D10B1-06D4-406E-8A8C-B61F647BB7C0Q27310060-0D257514-7EE1-4B11-8E34-B3F5FA91E7E6Q27853187-6154A88C-3633-48B8-BEF9-E727054AC63CQ28282708-900FC146-A573-495E-9AF4-B5308DE2020EQ30841513-655AD293-5F66-4964-93F8-CB15310A30C9Q33618570-59ACE930-8308-40E2-AE45-8E05D42D47CBQ33756997-D1953AE0-AFA6-42C5-8E84-2A5F4EEBFF20Q33764533-B0280FF9-6D97-4FB8-BB60-AA08A499BD8DQ33772355-6D9A3BD7-4853-4BDF-BED6-A4B5E40B49AEQ33946693-919321EC-71C9-4193-A1A7-D23A2FE80A7BQ34050798-71F0ED23-E52B-4DBD-93C0-F8BA9058CEBCQ34108929-2BF8AA48-2BD4-485D-AF7E-F2910EE23F7AQ34166553-EE92FD73-2A06-4EFF-9221-7B8EC9641AA6Q34205933-FC7FCD8C-41BE-49A2-BD4E-2903A8FE4F9CQ34264571-C241747B-E277-44B0-B28D-EA9F965335A7Q34511492-90B8E9AB-5C31-4EDC-8616-A2891CE7FF3BQ35035502-DE9F4ECF-7109-47DF-B412-954E4580725BQ35101347-0942366E-14E9-4633-8F2B-E8A8FB0216ABQ35135650-5EFDCCB6-4694-4C11-A9D2-6DB5AC25DD12Q35754390-FE1C7340-48AC-4B71-9A8B-8892A2BEC247Q35827814-B65050E0-0275-4CEC-8F43-4A9D423AA98DQ35925281-13EEE49D-31E6-4460-9840-EF47D5E200B4Q35946293-5981A705-94C8-4AAD-8758-4640522DB758Q35999183-FA9342CF-CACC-4B45-8A3F-67C56199670CQ36025964-4652D84D-E80A-4E83-848D-DD0984262F37Q36047046-35D9099D-7919-4C41-BD1B-50DC11923A25Q36048155-5F1033B1-F7BE-4F0E-9615-D22A40C589A6Q36174388-B25D4FEB-A3EB-4083-9613-D2C0B863D22DQ36296016-4B27BD4D-FBC0-40E6-A4F5-0411D436E157Q36367397-C5264F81-9955-474D-BE65-65EE8F357F54Q36460209-4D73FFE6-CDDA-42AC-8A2E-BDC5B48426B9Q36490004-0BFED281-A7B7-4341-AC5D-A359710AA326Q36619093-3459E869-6B5C-45E3-B6FE-AD7566357092Q36629427-F3540D06-8732-4A84-BF9C-A88F12970678Q36644748-63FA6A79-7D4C-48AC-9170-CF54840BC3CEQ36787522-7BC13686-177F-417B-8773-DA2770580296
P2860
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Definition of disease-risk str ...... logic, and molecular variables
@ast
Definition of disease-risk str ...... logic, and molecular variables
@en
type
label
Definition of disease-risk str ...... logic, and molecular variables
@ast
Definition of disease-risk str ...... logic, and molecular variables
@en
prefLabel
Definition of disease-risk str ...... logic, and molecular variables
@ast
Definition of disease-risk str ...... logic, and molecular variables
@en
P2093
P2860
P356
P1476
Definition of disease-risk str ...... logic, and molecular variables
@en
P2093
David W Ellison
Hisham Megahed
James Dalton
Mehmet Kocak
Meryl E Lusher
Roger E Taylor
Sarah Leigh Nicholson
Sarra L Ryan
Simon Bailey
Steven C Clifford
P2860
P304
P356
10.1200/JCO.2010.30.2810
P407
P577
2010-10-04T00:00:00Z